INTRODUCTION
Liver disease is associated with diverse metabolic derangements, involving both synthetic pathways and xenobiotic detoxification. The function of the trans-methylation pathway is impaired, with resulting hypermethioninaemia [ 13. Generation of sulphate via the trans-sulphuration pathway is also suboptimal [2] . The capacity to sulphate endogenous and exogenous compounds is dependent upon a continued supply of 3'-phosphoadenosine 5'-phosphosulphate (PAPS) [3] , which therefore partially regulates sulphation activity [4] . If the demand for sulphate exceeds the supply of PAPS, alternative conjugation pathways will be utilized, so the proportion of glucuronide conjugates increases. This can be particularly disadvantageous in the case of some hepatotoxic secondary monohydroxy bile acids and oestrogens, since glucuronide conjugates may be far more hepatotoxic than their respective sulphate conjugates . The rate-limiting step in the formation of sulphate is S-oxidation of cysteine to cysteine sulphinic acid, a reaction which is predominantly dependent upon activity of the enzyme cysteine dioxygenase [9, lo] .
Primary biliary cirrhosis (PBC) is a disease of unknown aetiology, which has been associated with an increased incidence of impaired S-oxidation, attributed putatively to impaired activity of cysteine dioxygenase [ 111. This could play an important role in disease pathogenesis, since S-oxidation and, in particular, activity of cysteine dioxygenase, is responsible for the intracellular supply of inorganic sulphate, the precursor of PAPS [12] . Impaired S-oxidation, and reduced activity of cysteine dioxygenase may be reflected by elevation of plasma cysteine and reduction of plasma sulphate [13] .
The aim of this study was to examine whether patients with PBC have an increase in the plasma cysteine/sulphate ratio, as further evidence of impaired sulphur metabolism. Comparison was made with patients suffering other forms of liver disease and patients with severe non-hepatic disease requiring treatment on an intensive therapy unit (ITU).
MATERIALS A N D METHODS

Subjects
Group 1. This comprised eight male and 32 female healthy subjects (median age 30 years), who all worked at the Queen Elizabeth Medical Centre. These controls did not take medication and they did not abuse alcohol. One-third were cigarette smokers, which was not significantly different from the disease groups.
Group 2. This comprised five males and 29 females (median age 52 years) with PBC. Their disease severity was graded according to Pugh's modification [14] of the Child's score [l5] accordingly: grade A, 10; grade B, 11; grade C, 13.
Group 3. This group comprised 13 males and 13 females (median age 46 years) with other liver diseases (OLD). These were graded by Child's Pugh score accordingly: grade A, 2; grade B, 10; grade C, 14. The diagnoses were: primary sclerosing cholangitis, 13; autoimmune chronic active hepatitis, four; cryptogenic cirrhosis, four; alcoholic cirrhosis, three; a,-antitrypsin deficiency, one; haemochromatosis, one.
Group 4. This group comprised 19 males and 14 females (median age 62 years) being treated on the ITU. Each had received no nutrition for at least 48 h, i.e. zero enteral or parenteral nutrition (excluding those calories infused for hydration or sedation). Liver function tests in these patients, including serum bilirubin, alkaline phosphatase and aspartate transaminase, were normal. Diagnoses included: laparotomy and abdominal surgery, 16; respiratory failure, eight; insertion of prosthetic heart valve, three; coronary artery by-pass surgery, three; repair of abdominal aortic aneurysm, two; Guillain Bark syndrome, one.
It was not possible to accurately match groups for age and sex, since the demographics of patient populations with different liver diseases (that is PBC compared with OLD) and on the general ITU vary greatly.
Written informed consent was obtained from all patients, and approval for the study was given by the local ethics committee.
All subjects were tested between 07.30 and 09.00 hours after an overnight fast. Venepuncture was performed and 7ml of blood was drawn into a lithium heparin tube and put immediately on ice. Plasma was separated and frozen within 15min in all cases, until the time of analysis.
Analyses
Cysteine. Cysteine was determined by the ninhydrin method of Gaitonde [16] . Plasma was deproteinized by 5% perchloric acid (1:1, v/v). This was centrifuged for 20 min at 2000g. Supernatant (1 ml) was added to a boiling tube containing 1 ml of acid ninhydrin reagent plus 1 ml of glacial acetic acid. Ninhydrin reagent was prepared using 250 mg of ninhydrin in 6 ml of glacial acetic acid and 4ml of concentrated hydrochloric acid. Tubes were vortexed, placed into a boiling water bath for lOmin, before rapid cooling. The volume of each tube was made up to lOml with 99% ethanol. A reagent blank was prepared as above using distilled water. The pink colour was read in a u.v.-visible spectrophotometer at 560nm against the blank. A calibration curve was constructed on each occasion that the assay was performed and unknown plasma concentrations were read from this.
Sulphate. The colorimetric analysis of Jackson and McCandless [17] was used. This is dependent on resultant turbidity from formation of a barium sulphate precipitate. A solution of BaCI, in agarose was prepared. Agarose was dissolved in water by gently heating, to a concentration of 0.01% (w/v). To this was added 0.5g of BaC1,/100ml of solution and allowed to stand overnight. Plasma was deproteinized by adding 0.7ml of sample to the same volume of 8% trichloroacetic acid. The sample was spun for 10min at 2000g, supernatant was removed and spun again for 10 min. To 0.55 ml of the second supernatant, 0.55 ml of 8% trichloroacetic acid was added, followed by 0.3 ml of the agarose/BaCl, solution. The purpose of agarose is to keep barium sulphate in suspension. A reagent blank was prepared using distilled water. Samples were vortexed and allowed to stand for 40min, after which the absorbance at 500nm was read. A calibration curve was constructed with potassium sulphate each time the assay was performed.
Protein. Protein determinations were performed using the Bio-Rad protein assay, [l8], modified by Bradford [19] . A standard curve was constructed using standard BSA each time the assay was performed. Bio-Rad reagent (5ml) was added to lop1 of plasma and the test tubes were vortexed. After 30min the blue colouring was fully developed and the absorbance of each sample was read at 595nm in the U.V. spectrophotometer, against the blank.
In each case, samples were taken in triplicate. A11 analyses were preceded by formation of a standard curve. Samples were analysed blind and in duplicate. The intra-assay variation was <5% for analysis of cysteine, sulphate and protein.
Statistical analysis
The Wilcoxon rank sum test [20] was applied for the comparison of quantitative biochemical data of plasma samples for cysteine, sulphate and cysteine/ sulphate ratio. The Kruskall-Wallis test was also applied to determine the statistical significance of variations of these parameters, within the liver disease groups, according to Child's Pugh score.
RESULTS
Plasma cysteine was expressed in nmol/mg of protein, plasma sulphate was expressed in nmol/mg of protein and the plasma cysteine/sulphate ratio was calculated. Results are represented graphically in Fig. 1 . Plasma cysteine was lower in healthy subjects than in the disease groups. The differences were highly significant (healthy control subjects versus patients with PBC, P <O.OOOl; versus patients with OLD, P<O.OOOl; versus ITU patients, P<O.O001). Plasma cysteine was lower in PBC patients than OLD patients, but the difference was not statistically significant (P = 0.15). Plasma cysteine in ITU patients was greatly elevated compared with all other groups (compared with healthy control subjects, P <0.0001; with PBC patients, P <0.0001 and OLD patients, P <O.OoOl).
Plasma sulphate was higher in healthy control subjects (1.37 nmol/mg of protein) than any disease group. The difference was significant only when compared with PBC patients (P <0.05) (compared with OLD patients, P=O.lO; compared with ITU patients, P=O.14). Plasma sulphate was lower in patients with PBC than patients with OLD, but not significantly (P = 0.57). There was a non-significant reduction in patients with PBC compared with ITU patients (P = 0.44).
The plasma cysteine/sulphate ratio in healthy control subjects (0.095) was significantly lower than that in all other groups (P<O.OOOl for all groups). The ratio in patients with PBC was not significantly different from that in patients with OLD (P=O.98). The ratio in ITU patients (1.650) was higher than that in all other groups (P<0.0001).
Because groups were poorly sex-matched, a separate analysis solely of females was performed. Females with PBC (n = 29) and healthy control females (n = 32) were compared using the Wilcoxon rank sum test [median plasma cysteine of PBC, 0.36, healthy control, 0.12 nmol/mg of protein (P < O.OOO1); median plasma sulphate PBC, 0.8 15, healthy control, 1.52 nmol/mg of protein (Pc0.05); median plasma cysteine/sulphate ratio, PBC, 0.473, healthy control, 0.088 (P<O.OOOl)].
Analysis of plasma cysteine and sulphate levels by Child's Pugh grade
Results are represented graphically in Fig. 2 The plasma cysteine/sulphate ratio did not show consistent change with grade of liver disease. Grade A (ratio 0.591) was highest and grade B (ratio 0.358) the lowest. Only the difference between grades B and C (ratio 0.571) was significant (P<0.05). The other differences were not significant (grade A versus grade B, P=0.28; grade A versus grade C, P = 0.68).
Application of Kruskall-Wallis analysis, with two degrees of freedom, showed a significant difference in plasma cysteine values between the Child's Pugh groups ( P = 0.002), but no significant difference between plasma sulphate ( P = 0.09) or the plasma cysteine/sulphate ratio ( P = 0.18).
DISCUSS10 N
This study analyses plasma cysteine and sulphate in liver disease and an heterogeneous group of ITU patients. Plasma cysteine and sulphate varied widely in disease. PBC was associated with an increase in plasma cysteine, concurrent with a low plasma sulphate. However, the effect was not diseasespecific, as plasma cysteine rose in all forms of liver disease studied, the increment correlating with disease severity, as measured by Child's Pugh grade. An additional group of patients, enduring a prolonged state of fasting on ITU, were studied. Plasma cysteine was more elevated in this group than in patients with liver disease.
Elevation of cysteine in plasma appears to be a non-specific reflection of 'disease', although the feature common to all groups was malnutrition. ITU patients were fasting, while patients with liver disease usually have muscle wasting and negative nitrogen balance [21, 22] , which will release amino acids, including cysteine, into the plasma from tissue breakdown. Although impairment of the transsulphuration pathway could lead to reduced concentrations of cysteine [22, 23] , in practice the impairment of oxidative degradation of cysteine derived from tissues appears to outweigh this effect.
Cysteine occurs in plasma as the 'free' amino acid, containing a thiol group, as the disulphide dimer, cystine, and also bound to protein, linked through a thiol grouping [24] . When plasma samples are first taken, most of the cysteine (2595%) exists in the free form, although cystine and cysteine-protein dimers form if the sample is left to stand. Cysteine itself is not readily measured by the standard amino acid analyser method, which converts it to cystine and cysteic acid before determination. The inaccuracies of the amino acid analyser method have been discussed by Malloy et al. [25] . The colorimetric method used in our assays gives far higher readings for cysteine in plasma as it is designed to be specific and transsulphuration [2], with reduced activity of Sadenosylmethionine synthetase, hypermethioninaemia and impaired capacity to metabolize a methionine load [2] . There are a number of pathways by which plasma cysteine can be oxidized to generate inorganic sulphate. The cytosolic enzyme cysteine dioxygenase is believed to be quantitatively the most important in man [9,11,12], although a mitochondrial pathway is also known to exist [30] . This mitochondrial pathway is enhanced by glutathione (glutamyl-cysteinyl-glycine), the synthesis of which is driven by cysteine concentrations. It seems possible, therefore, that a 'feedback' mechanism exists, in which high plasma cysteine indirectly activates a mitochondrial system of oxidative enzymes. Inhibition of either or both pathways in critical disease would lead to raised cysteine levels; the controlling factor may be the capacity of glutathione synthetase, as decreased glutathione is known to occur in cirrhosis [2], despite high cysteine levels. Whatever the precise aetiology of these defects, they will tend to impair detoxication pathways via glutathione conjugation or sulphate formation, and will therefore increase susceptibility to both endogenous and exogenous toxins.
In summary, major alterations occur in plasma levels of cysteine and sulphate in disease states. The plasma cysteine/sulphate ratio is greatly elevated both in liver disease and an heterogeneous ITU population. Because these effects are not specific to PBC, they are more likely to represent interference in the trans-sulphuration pathway and alterations in the balance of protein turnover, rather than a primary influence of the proposed genetic polymorphism in PBC. These metabolic changes may progressively diminish the capacity of the liver and other tissues to detoxify xenobiotics and endogenously derived toxins as disease advances.
